<p>The Pharma-to-FMCG Player Is Leveraging Its Herbal Equity to Gain Market Share in Other Categories. Can It Win?</p>

- Himanshu Kakkar

It is rare to find men like Philipe Haydon in India’s corporate world. The fact that he isn’t a promoter but has still put in 37 years with a company makes him one of a kind. He started off as a medical representative and moved up over three decades to become the company’s CEO in 2007. Go deeper and you will discover that within the pharma-to-FMCG herbal company, longevity isn’t the exception; it’s rather the rule. “Barring personal care, all other division heads are people who have spent decades in Himalaya. The biggest advantage is that there is no change in vision or value system,” says Haydon.

The founder family and also chairman Meraj Manal is known to believe that continuity brings progress. And, the company’s progress hasn’t skipped competition’s attention. “On a monthly basis, our chairman gets one or two offers from MNCs to buy Himalaya. But it is not up for sale, it will never be. It will always remain privately held,” Haydon disappoints the prospective buyers.

Himalaya Drug Company was founded by M Manal in 1934 when he felt that converting the unfriendly powders, mixes, and herbs into tablets can help people take up Ayurveda. Later, when he validated Ayurveda with scientific research, the company also managed to convince medic

Esta historia es de la edición February 3, 2017 de Outlook Business.

Suscríbete a Magzter GOLD para acceder a miles de historias premium seleccionadas y a más de 9000 revistas y periódicos.

SUSCRÍBETE AHORA

¿Ya eres suscriptor? Iniciar sesión